US5066789A
(en)
*
|
1988-09-30 |
1991-11-19 |
Neorx Corporation |
Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
|
DE68924783T2
(de)
*
|
1988-09-30 |
1996-03-28 |
Neorx Corp |
Wässrige additivsysteme, verfahren und polymerteilchen.
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5154924A
(en)
*
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US6610299B1
(en)
|
1989-10-19 |
2003-08-26 |
Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US7241595B2
(en)
*
|
1989-10-20 |
2007-07-10 |
Sanofi-Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US6475486B1
(en)
|
1990-10-18 |
2002-11-05 |
Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
GB9017024D0
(en)
*
|
1990-08-03 |
1990-09-19 |
Erba Carlo Spa |
New linker for bioactive agents
|
CA2048089A1
(en)
*
|
1990-09-17 |
1992-03-18 |
Wolfgang A. Wrasidlo |
Chemical conjugation of morpholino anthracyclines to antibodies
|
GB9026491D0
(en)
*
|
1990-12-05 |
1991-01-23 |
Erba Carlo Spa |
Anthracycline-conjugates
|
US5776458A
(en)
*
|
1990-12-05 |
1998-07-07 |
Pharmacia & Upjohn S.P.A. |
Anthracycline-conjugates
|
US5272253A
(en)
*
|
1991-07-01 |
1993-12-21 |
Eli Lilly And Company |
Cluster conjugates of drugs with antibodies
|
US5622929A
(en)
*
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
US5505931A
(en)
*
|
1993-03-04 |
1996-04-09 |
The Dow Chemical Company |
Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
|
GR1001459B
(el)
*
|
1992-10-08 |
1993-12-30 |
Lilly Co Eli |
Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
|
DE4236237A1
(de)
*
|
1992-10-27 |
1994-04-28 |
Behringwerke Ag |
Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
|
US5556623A
(en)
*
|
1993-03-30 |
1996-09-17 |
Eli Lilly And Company |
Antibody-drug conjugates
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
DE4435087A1
(de)
*
|
1994-09-30 |
1996-04-04 |
Deutsches Krebsforsch |
Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
US5843903A
(en)
*
|
1995-11-27 |
1998-12-01 |
The Administrators Of The Tulane Educational Fund |
Targeted cytotoxic anthracycline analogs
|
WO1997023243A1
(en)
*
|
1995-12-22 |
1997-07-03 |
Bristol-Myers Squibb Company |
Branched hydrazone linkers
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
CA2264610A1
(en)
*
|
1996-11-05 |
1998-05-14 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
CA2248592A1
(en)
*
|
1998-08-31 |
2000-02-29 |
Christopher D. Batich |
Microspheres for use in the treatment of cancer
|
GB9917012D0
(en)
*
|
1999-07-20 |
1999-09-22 |
Pharmacia & Upjohn Spa |
Combined preparations comprising antitumor agents
|
US20060014684A1
(en)
*
|
2000-03-03 |
2006-01-19 |
University Technologies International Inc. |
Novel uses of EGF
|
US6586207B2
(en)
|
2000-05-26 |
2003-07-01 |
California Institute Of Technology |
Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
|
EP1294404A2
(de)
*
|
2000-06-14 |
2003-03-26 |
Corixa Corporation |
Prodrugverbindungen mit isoleucinreste enthaltenden oligopeptiden
|
US6624317B1
(en)
|
2000-09-25 |
2003-09-23 |
The University Of North Carolina At Chapel Hill |
Taxoid conjugates as antimitotic and antitumor agents
|
EP1355672A2
(de)
|
2000-12-01 |
2003-10-29 |
Cell Works Inc. |
"konjugate von glykosylierten/galaktosylierten peptiden, bifunktionellen linkern und nukleotid?monomeren/polymeren, damit zusammenhängende zusammensetzungen, sowie verfahren zu ihrer verwendung"
|
AU2002216864A1
(en)
*
|
2000-12-21 |
2002-07-01 |
Mcgill University |
Conjugates of antibodies and anticancer drugs
|
US7445802B2
(en)
*
|
2000-12-26 |
2008-11-04 |
Yeda Research And Development Co. Ltd |
Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
PT1392359E
(pt)
|
2001-05-11 |
2010-01-27 |
Ludwig Inst For Cancer Res Ltd |
Proteínas de ligação específica e suas utilizações
|
WO2002092116A1
(en)
*
|
2001-05-15 |
2002-11-21 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of drugs for the treatment of viral infections
|
JP2005507919A
(ja)
*
|
2001-10-26 |
2005-03-24 |
ユニヴァーシティ・テクノロジーズ・インターナショナル・インコーポレーテッド |
泌尿生殖器経路の病原感染を阻害するためのegfの使用
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
SI2357006T1
(sl)
*
|
2002-07-31 |
2016-01-29 |
Seattle Genetics, Inc. |
Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
|
JP4959136B2
(ja)
|
2002-12-13 |
2012-06-20 |
イミューノメディクス、インコーポレイテッド |
細胞内で開裂可能な結合を有する免疫接合体
|
AU2004213053C1
(en)
|
2003-02-20 |
2009-07-16 |
Seagen Inc. |
Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
US20040171175A1
(en)
*
|
2003-02-28 |
2004-09-02 |
Swanson Basil I. |
Process for conjugating biomolecules to hydrophobic membrane-incorporated molecules
|
US20040220084A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for nucleic acid delivery
|
US20040219097A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the diagnosis, imaging and treatment of tumors
|
US20040219101A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for treatment of tumors
|
US20040220085A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for nucleic acid delivery
|
US20040219102A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for drug delivery
|
US20040219103A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods useful for the diagnosis, imaging and treatment of tumors
|
US20040219099A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Method for the treatment of tumors
|
US20040219100A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the treatment of tumors
|
US20040219104A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for treatment of tumors
|
US20040220121A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for drug delivery
|
US20040220390A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the treatment of tumors
|
US9011880B2
(en)
*
|
2003-10-21 |
2015-04-21 |
Igf Oncology, Llc |
Compounds and methods for treating cancer
|
CA2542834C
(en)
*
|
2003-10-21 |
2012-04-24 |
Igf Oncology, Llc |
Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents
|
CA2543888C
(en)
|
2003-11-06 |
2016-01-19 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
WO2005072292A2
(en)
*
|
2004-01-24 |
2005-08-11 |
Hugh Mctavish |
Methods for enhancing radiation therapy
|
US20050175619A1
(en)
*
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
US20050287639A1
(en)
|
2004-05-17 |
2005-12-29 |
California Institute Of Technology |
Methods of incorporating amino acid analogs into proteins
|
WO2006047214A2
(en)
*
|
2004-10-21 |
2006-05-04 |
Igf Oncology, Llc |
Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer
|
ATE476994T1
(de)
|
2004-11-30 |
2010-08-15 |
Curagen Corp |
Antikörper gegen gpnmb und ihre verwendungen
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US7569358B2
(en)
*
|
2005-03-30 |
2009-08-04 |
Saladax Biomedical Inc. |
Doxorubicin immunoassay
|
HUE026303T2
(hu)
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
US8052971B2
(en)
*
|
2005-11-21 |
2011-11-08 |
MG Biologics |
Oral use of specific antibodies for intestinal health
|
BRPI0708299A2
(pt)
*
|
2006-02-27 |
2011-05-24 |
Univ Leland Stanford Junior |
composições e métodos para o transporte de moléculas com propriedades melhoradas de liberação através de barreiras biológicas
|
CA2647632C
(en)
|
2006-03-27 |
2017-06-27 |
University Of Maryland Biotechnology Institute |
Glycoprotein synthesis and remodeling by enzymatic transglycosylation
|
CA2699837C
(en)
|
2006-12-01 |
2017-06-13 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
MX338185B
(es)
|
2007-01-25 |
2016-04-05 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
JP5618549B2
(ja)
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
|
ES2528922T3
(es)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
|
DK2474557T3
(da)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
CA2696360C
(en)
|
2007-08-14 |
2018-11-20 |
Ludwig Institute For Cancer Research |
Monoclonal antibody targeting the egfr receptor and uses thereof
|
AU2008308509B2
(en)
|
2007-10-04 |
2014-10-23 |
Zymogenetics, Inc. |
B7 family member zB7H6 and related compositions and methods
|
AU2009205995B2
(en)
|
2008-01-18 |
2014-04-03 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
AU2009210636B2
(en)
|
2008-01-31 |
2014-08-28 |
Genentech, Inc. |
Anti-CD79b antibodies and immunoconjugates and methods of use
|
WO2009099741A1
(en)
*
|
2008-02-01 |
2009-08-13 |
Genentech, Inc. |
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
|
MX2011000509A
(es)
|
2008-07-15 |
2011-04-05 |
Genentech Inc |
Conjugados derivados de antraciclina, proceso para su preparacion y su uso como compuestos antitumorales.
|
WO2010014236A2
(en)
*
|
2008-07-30 |
2010-02-04 |
The University Of North Carolina At Chapel Hill |
Acylhydrazone-based cleavable linkers
|
RU2012101999A
(ru)
|
2009-06-22 |
2013-07-27 |
МЕДИММЬЮН, ЭлЭлСи |
РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
TWI583394B
(zh)
|
2009-10-23 |
2017-05-21 |
千禧製藥公司 |
抗-gcc抗體分子及其相關之組合物及方法
|
PT2510011E
(pt)
|
2009-12-09 |
2014-12-12 |
Inst Nat Santé Et De La Rech Médicale |
Anticorpos monoclonais que se ligam a b7h6 e suas utilizações
|
UA115517C2
(uk)
|
2010-02-08 |
2017-11-27 |
Ейдженсіс, Інк. |
Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 161p2f10b
|
HUE046360T2
(hu)
|
2010-03-12 |
2020-03-30 |
Debiopharm Int Sa |
CD37-kötõ molekulák és azok immunkonjugátumai
|
CN105585630B
(zh)
|
2010-07-29 |
2020-09-15 |
Xencor公司 |
具有修改的等电点的抗体
|
TWI651096B
(zh)
|
2010-09-29 |
2019-02-21 |
美商艾澤西公司 |
與191p4d12蛋白結合之抗體藥物共軛物(adc)
|
EP3828205A1
(de)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1-antikörper
|
CN103270043B
(zh)
|
2010-12-02 |
2015-12-16 |
内尔维阿诺医学科学有限公司 |
用于制备吗啉基蒽环衍生物的方法
|
ES2719548T3
(es)
|
2010-12-06 |
2019-07-11 |
Seattle Genetics Inc |
Anticuerpos humanizados para liv-1 y uso de los mismos para tratar el cáncer
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012135740A2
(en)
|
2011-04-01 |
2012-10-04 |
Immunogen, Inc. |
Cd37-binding molecules and immunoconjugates thereof
|
CA2833820C
(en)
|
2011-05-27 |
2019-10-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
EP3611187A1
(de)
|
2011-10-10 |
2020-02-19 |
Xencor, Inc. |
Verfahren zur aufreinigung von antikörpern
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
RU2675319C2
(ru)
|
2011-11-04 |
2018-12-18 |
Займворкс Инк. |
РАЗРАБОТКА СТАБИЛЬНОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В ДОМЕНЕ Fc
|
EP2592103A1
(de)
|
2011-11-08 |
2013-05-15 |
Adriacell S.p.A. |
Polymeraldehydderivate
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
JP2015505537A
(ja)
|
2012-01-20 |
2015-02-23 |
シー レーン バイオテクノロジーズ, エルエルシー |
結合分子コンジュゲート
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US9816066B2
(en)
|
2012-04-24 |
2017-11-14 |
The Regents Of The University Of California |
Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
|
KR20150006000A
(ko)
|
2012-05-01 |
2015-01-15 |
제넨테크, 인크. |
항-pmel17 항체 및 면역접합체
|
EA037203B1
(ru)
|
2012-05-15 |
2021-02-18 |
Сиэтл Джинетикс, Инк. |
Конъюгаты антитело-лекарственное средство с самостабилизирующимися линкерами
|
WO2014011521A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti - cd79b antibodies
|
BR112015000439A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
UA118251C2
(uk)
|
2012-08-23 |
2018-12-26 |
Ейдженсіс, Інк. |
Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 158p1d7
|
ES2701076T3
(es)
|
2012-11-24 |
2019-02-20 |
Hangzhou Dac Biotech Co Ltd |
Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
HUE057977T2
(hu)
|
2012-12-13 |
2022-06-28 |
Immunomedics Inc |
Ellenanyagok és SN-38 immunkonjugátumainak dózisai javított hatásossággal és csökkentett toxicitással
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
LT2943511T
(lt)
|
2013-01-14 |
2019-11-11 |
Xencor Inc |
Nauji heterodimeriniai baltymai
|
EP2945969A1
(de)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
|
TR201908761T4
(tr)
|
2013-02-22 |
2019-07-22 |
Abbvie Stemcentrx Llc |
Antidll3-antikor-pbd konjugatları ve kullanımları.
|
EP3299391B1
(de)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4-antikörper und immunkonjugate
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
CA2906927C
(en)
|
2013-03-15 |
2021-07-13 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
CA2902739C
(en)
|
2013-03-15 |
2022-11-22 |
Xencor, Inc. |
Heterodimeric proteins
|
SG11201507619PA
(en)
|
2013-03-15 |
2015-10-29 |
Ct For Drug Res And Dev |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
JP6510518B2
(ja)
|
2013-08-01 |
2019-05-08 |
アジェンシス,インコーポレイテッド |
Cd37タンパク質に結合する抗体薬物結合体(adc)
|
CN105848671B
(zh)
|
2013-08-28 |
2019-12-13 |
艾伯维施特姆森特克斯有限责任公司 |
位点特异性抗体缀合方法和组合物
|
WO2015031541A1
(en)
|
2013-08-28 |
2015-03-05 |
Stem Centrx, Inc. |
Novel sez6 modulators and methods of use
|
RU2016109247A
(ru)
|
2013-09-17 |
2017-10-19 |
Дженентек, Инк. |
Способы применения антител к lgr5
|
CN105813654B
(zh)
|
2013-10-11 |
2019-05-31 |
美国政府(由卫生和人类服务部的部长所代表) |
Tem8抗体及其用途
|
AU2014333563B9
(en)
|
2013-10-11 |
2020-04-02 |
Oxford Biotherapeutics Ltd |
Conjugated antibodies against LY75 for the treatment of cancer
|
DK3057585T3
(da)
|
2013-10-15 |
2020-10-19 |
Seagen Inc |
Pegylerede lægemiddel-linkere til forbedret ligandlægemiddelkonjugat-farmakokinetik
|
WO2015061206A2
(en)
|
2013-10-21 |
2015-04-30 |
North Carolina State University |
Methods and constructs for compound delivery
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
KR102306493B1
(ko)
|
2013-11-25 |
2021-09-28 |
씨젠 인크. |
접합을 위한 cho 세포 배양물로부터의 항체 제조
|
EP3080164B1
(de)
|
2013-12-13 |
2019-01-16 |
Genentech, Inc. |
Anti-cd33-antikörper und immunkonjugate
|
CA2928952A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
WO2015095953A1
(en)
|
2013-12-27 |
2015-07-02 |
The Centre For Drug Research And Development |
Sulfonamide-containing linkage systems for drug conjugates
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
EP3092254A4
(de)
|
2014-01-10 |
2017-09-20 |
Birdie Biopharmaceuticals Inc. |
Verbindungen und zusammensetzungen zur behandlung von her2-positiven tumoren
|
JP6835590B2
(ja)
|
2014-01-12 |
2021-02-24 |
アイジーエフ オンコロジー、 エルエルシー |
インスリン様成長因子−1および上皮増殖因子を含む融合タンパク質およびそのバリアントならびにその使用
|
EP3107576A4
(de)
|
2014-02-21 |
2017-09-06 |
Abbvie Stemcentrx LLC |
Anti-dll3-antikörper und arzneimittelkonjugate zur verwendung in melanomen
|
EP3122757B1
(de)
|
2014-02-28 |
2023-09-06 |
Hangzhou Dac Biotech Co., Ltd |
Geladene linker und deren verwendungen zur konjugation
|
KR20220123560A
(ko)
|
2014-03-21 |
2022-09-07 |
애브비 인코포레이티드 |
항-egfr 항체 및 항체 약물 접합체
|
US10300070B2
(en)
|
2014-03-27 |
2019-05-28 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
UA119167C2
(uk)
|
2014-03-28 |
2019-05-10 |
Зенкор, Інк. |
Біспецифічне антитіло, яке зв'язується з cd38 та cd3
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック, インコーポレイテッド |
抗gpc3抗体及びイムノコンジュゲート
|
CA2956178A1
(en)
|
2014-07-24 |
2016-01-28 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
EP3388449A3
(de)
|
2014-09-12 |
2018-10-24 |
F. Hoffmann-La Roche AG |
Cystein-manipulierte antikörper und konjugate
|
BR112017004631A2
(pt)
|
2014-09-12 |
2018-01-30 |
Genentech, Inc. |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento, de inibição da proliferação de uma célula e de detecção de her2 humana e método para a detecção de um câncer
|
US10149913B2
(en)
|
2014-09-12 |
2018-12-11 |
Genentech, Inc. |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
US9751946B2
(en)
|
2014-09-12 |
2017-09-05 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
DK3194421T3
(da)
|
2014-09-17 |
2022-02-14 |
Zymeworks Inc |
Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
|
SI3262071T1
(sl)
|
2014-09-23 |
2020-07-31 |
F. Hoffmann-La Roche Ag |
Način uporabe imunokonjugatov proti CD79b
|
RS61431B1
(sr)
|
2014-11-19 |
2021-03-31 |
Axon Neuroscience Se |
Humanizovana antitela na tau u alchajmerovoj bolesti
|
IL252480B2
(en)
|
2014-11-26 |
2023-12-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
CA2968878A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
US10472395B2
(en)
|
2015-03-05 |
2019-11-12 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
BR112017019062A2
(pt)
|
2015-03-09 |
2018-04-17 |
Agensys Inc |
conjugados de anticorpo-fármaco (adc) que se ligam a proteínas flt3
|
EP3280454A1
(de)
|
2015-04-07 |
2018-02-14 |
Memorial Sloan Kettering Cancer Center |
Nanopartikel-immunkonjugate
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
EP3091033A1
(de)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3-antikörper und verwendungen davon
|
EP3302561A4
(de)
|
2015-06-08 |
2019-02-06 |
Debiopharm International SA |
Kombinationen aus anti-cd37-immunkonjugat und anti-cd20-antikörper
|
EP3845557B1
(de)
|
2015-06-12 |
2023-08-02 |
Lentigen Technology, Inc. |
Verfahren zur behandlung von krebs mit veränderten t-zellen
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
WO2017004330A1
(en)
|
2015-06-30 |
2017-01-05 |
Seattle Genetics, Inc. |
Anti-ntb-a antibodies and related compositions and methods
|
EP3319936A4
(de)
|
2015-07-12 |
2019-02-06 |
Suzhou M-conj Biotech Co., Ltd. |
Brückenlinker zur konjugation von zellbindenden molekülen
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
BR112018003147A2
(pt)
|
2015-08-28 |
2018-09-18 |
Debiopharm International S.A. |
anticorpos e testes para detecção de cd37
|
EP3347047A1
(de)
|
2015-09-09 |
2018-07-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Expressionsvektor-abgabesystem und dessen verwendung zur induzierung einer immunantwort
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
JP6821688B2
(ja)
|
2015-10-09 |
2021-01-27 |
ミルテニー・バイオテク・テクノロジー・インコーポレイテッドMiltenyi Biotec Technology, Inc. |
キメラ抗原受容体および使用方法
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
US10227410B2
(en)
|
2015-12-07 |
2019-03-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
EP3419655A1
(de)
|
2016-02-27 |
2019-01-02 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Peptidimpfstoffe mit selbstanordnenden polymernanopartikeln
|
MY189113A
(en)
|
2016-03-02 |
2022-01-26 |
Eisai R&D Man Co Ltd |
Eribulin-based antibody-drug conjugates and methods of use
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
BR112018069273A2
(pt)
|
2016-03-25 |
2019-01-22 |
Seattle Genetics Inc |
métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco
|
JP2019522960A
(ja)
|
2016-04-21 |
2019-08-22 |
アッヴィ・ステムセントルクス・エル・エル・シー |
新規の抗bmpr1b抗体及び使用方法
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
RU2725292C2
(ru)
|
2016-04-27 |
2020-06-30 |
Иммьюномедикс, Инк. |
Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
|
HRP20221298T1
(hr)
|
2016-05-13 |
2022-12-23 |
Bioatla, Inc. |
Anti-ror2 protutijela, fragmenti protutijela, njihovi imunokonjugati i njihove uporabe
|
EP3465221B1
(de)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
|
TW202304996A
(zh)
|
2016-06-08 |
2023-02-01 |
美商艾伯維有限公司 |
抗-b7-h3抗體及抗體藥物結合物
|
US20200147235A1
(en)
|
2016-06-08 |
2020-05-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
CN109641962A
(zh)
|
2016-06-08 |
2019-04-16 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
BR112018075653A2
(pt)
|
2016-06-08 |
2019-08-27 |
Abbvie Inc |
anticorpos anti-b7-h3 e conjugados anticorpo fármaco
|
JP2019524651A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
MA45255A
(fr)
|
2016-06-14 |
2019-04-17 |
Xencor Inc |
Anticorps inhibiteurs de points de contrôle bispécifiques
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
BR112019001945A2
(pt)
|
2016-08-09 |
2019-05-07 |
Seattle Genetics, Inc. |
composição de conjugado de fármaco aglutinante, formulação farmaceuticamente aceitável, métodos para tratar uma doença ou afecção hiperproliferativa, para inibir a multiplicação de uma célula tumoral ou célula cancerígena e para preparar uma composição de conjugado de fármaco aglutinado, e, composto
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018045245A1
(en)
|
2016-09-02 |
2018-03-08 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
WO2018045325A1
(en)
|
2016-09-02 |
2018-03-08 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
SG11201903302UA
(en)
|
2016-10-14 |
2019-05-30 |
Xencor Inc |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
EP3535297B1
(de)
|
2016-11-02 |
2022-08-10 |
Debiopharm International, S.A. |
Verfahren zur verbesserung einer anti-cd37-immunokonjugattherapie
|
KR20220147721A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
EP4015532A1
(de)
|
2016-11-21 |
2022-06-22 |
cureab GmbH |
Anti-gp73-antikörper und immunkonjugate
|
CA3096798A1
(en)
|
2017-01-09 |
2018-07-12 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
EP3589654A1
(de)
|
2017-03-02 |
2020-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antikörper mit spezifität gegen nectin-4 und verwendungen davon
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
WO2018175988A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
SG11201908325PA
(en)
|
2017-03-24 |
2019-10-30 |
Seattle Genetics Inc |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
JP2020512314A
(ja)
|
2017-03-27 |
2020-04-23 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
サシツズマブゴビテカンとRAD51阻害剤を用いたTrop−2発現トリプルネガティブ乳癌の治療
|
EP3606964A4
(de)
|
2017-04-03 |
2020-12-09 |
Immunomedics, Inc. |
Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
|
BR112019020853A2
(pt)
|
2017-04-04 |
2020-05-12 |
Avidea Technologies, Inc. |
Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune
|
US20230190796A1
(en)
|
2017-04-07 |
2023-06-22 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
WO2018195302A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
CN110637036A
(zh)
|
2017-04-28 |
2019-12-31 |
味之素株式会社 |
具有针对可溶性蛋白质的亲和性物质、切割性部分及反应性基团的化合物或其盐
|
KR20200000438A
(ko)
|
2017-05-21 |
2020-01-02 |
아이쥐에프 온콜로지, 엘엘씨 |
골수이형성 증후군을 치료하기 위한 인슐린양 성장 인자-화학치료학적 접합체
|
CA3067603A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
EP3652540A4
(de)
|
2017-07-12 |
2021-04-07 |
The Johns Hopkins University |
Auf proteoliposom basierendes znt-8-selbstantigen zur diagnose von typ-1-diabetes
|
WO2019028051A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
|
EP3668600A1
(de)
|
2017-08-10 |
2020-06-24 |
Abionyx Pharma SA |
Cargomere
|
US10501539B2
(en)
|
2017-09-15 |
2019-12-10 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-CD19 immunotherapy
|
US10543263B2
(en)
|
2017-10-16 |
2020-01-28 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-CD22 immunotherapy
|
WO2019081455A1
(en)
|
2017-10-23 |
2019-05-02 |
Mablink Bioscience |
LIGAND-MEDICINAL CONJUGATE COMPRISING A UNIQUE MOLECULAR WEIGHT POLYSARCOSIN
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
CN111448213A
(zh)
|
2017-12-01 |
2020-07-24 |
西雅图基因公司 |
Cd47抗体及其用于治疗癌症的用途
|
BR112020010937A2
(pt)
|
2017-12-01 |
2020-11-17 |
Seattle Genetics, Inc. |
anticorpos anti-liv1 humanizados para o tratamento de câncer de mama
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
WO2019126464A2
(en)
|
2017-12-20 |
2019-06-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating hiv/aids with immunotherapy
|
US20210024628A1
(en)
|
2018-03-22 |
2021-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
EP3768714A1
(de)
|
2018-03-23 |
2021-01-27 |
Seagen Inc. |
Verwendung von antikörper-wirkstoff-konjugaten mit tubulinzerstörungsmitteln zur behandlung von soliden tumoren
|
MX2020009991A
(es)
|
2018-03-28 |
2020-10-14 |
Axon Neuroscience Se |
Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
AU2019256529A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
US11524991B2
(en)
|
2018-04-18 |
2022-12-13 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
EP3796943A2
(de)
|
2018-05-22 |
2021-03-31 |
Avidea Technologies, Inc. |
Verbesserte verfahren zur herstellung von impfstoffen auf peptidbasis
|
JP7390315B2
(ja)
|
2018-06-01 |
2023-12-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
|
CA3103143A1
(en)
|
2018-06-14 |
2019-12-19 |
Ajinomoto Co., Inc. |
Compound having affinity substance to antibody, cleavable portion, and reactive group, or salt thereof
|
WO2019240288A1
(ja)
|
2018-06-14 |
2019-12-19 |
味の素株式会社 |
抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
WO2020010079A2
(en)
|
2018-07-02 |
2020-01-09 |
Amgen Inc. |
Anti-steap1 antigen-binding protein
|
WO2020061498A1
(en)
|
2018-09-20 |
2020-03-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd123 immunotherapy
|
AU2019350865A1
(en)
|
2018-09-26 |
2021-04-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with Anti-CD19/CD22 immunotherapy
|
KR20210069641A
(ko)
|
2018-10-03 |
2021-06-11 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
EP3860646A1
(de)
|
2018-10-03 |
2021-08-11 |
Avidea Technologies, Inc. |
Aromatische ringsubstituierte amphiphile polymere als wirkstoffabgabesysteme
|
EP3882261A4
(de)
|
2018-10-31 |
2023-02-08 |
Ajinomoto Co., Inc. |
Verbindung mit substanz mit affinität für antikörper, spaltstelle und reaktive gruppe oder salz davon
|
US11103533B2
(en)
|
2018-11-30 |
2021-08-31 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD38 immunotherapy
|
JP2022512401A
(ja)
|
2018-12-13 |
2022-02-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
|
US20220088204A1
(en)
*
|
2019-01-25 |
2022-03-24 |
Yale University |
Anticancer drugs and methods of making and using same
|
MX2021009138A
(es)
|
2019-02-05 |
2021-09-10 |
Seagen Inc |
Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco.
|
US11472890B2
(en)
|
2019-03-01 |
2022-10-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
WO2020181164A1
(en)
|
2019-03-06 |
2020-09-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
CN114174340A
(zh)
|
2019-03-20 |
2022-03-11 |
加利福尼亚大学董事会 |
密封蛋白-6抗体和药物缀合物
|
CN114585388A
(zh)
|
2019-04-17 |
2022-06-03 |
阿维迪科技公司 |
用于配体展示和/或药物递送的星形聚合物的组合物和制造方法
|
EP3958908A1
(de)
|
2019-04-24 |
2022-03-02 |
Heidelberg Pharma Research GmbH |
Amatoxin-antikörper-wirkstoff-konjugate und verwendungen davon
|
US11052112B2
(en)
|
2019-05-30 |
2021-07-06 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-BCMA immunotherapy
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
US20220306727A1
(en)
|
2019-06-05 |
2022-09-29 |
Seagen Inc. |
Methods of Purifying Masked Antibodies
|
MX2022000174A
(es)
|
2019-07-02 |
2022-05-20 |
Us Health |
Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
|
WO2021016233A1
(en)
|
2019-07-22 |
2021-01-28 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
MX2022003517A
(es)
|
2019-10-04 |
2022-04-25 |
Seagen Inc |
Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
|
KR20220079590A
(ko)
|
2019-10-04 |
2022-06-13 |
티에이이 라이프 사이언시스 |
Fc 돌연변이 및 부위-특이적인 접합 성질을 포함하는 항체 조성물
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
JP2023509760A
(ja)
|
2020-01-08 |
2023-03-09 |
シンシス セラピューティクス,インコーポレイテッド |
Alk5阻害剤複合体およびその使用
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
EP4149558A1
(de)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
JP2023528412A
(ja)
|
2020-06-05 |
2023-07-04 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
抗bcma抗体-薬物コンジュゲート及び使用方法
|
JPWO2021251358A1
(de)
|
2020-06-09 |
2021-12-16 |
|
|
CA3171101A1
(en)
|
2020-06-22 |
2021-12-30 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
EP4192871A1
(de)
|
2020-08-04 |
2023-06-14 |
Seagen Inc. |
Anti-cd282-antikörper und antikörper-wirkstoff-konjugate
|
EP3970752A1
(de)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Moleküle mit löslichkeitsmarkierung und zugehörige verfahren
|
EP4216927A1
(de)
|
2020-09-22 |
2023-08-02 |
Vaccitech North America, Inc. |
Zusammensetzungen und verfahren zur herstellung amphiphiler blockcopolymere zur in-situ-bildung von nanopartikeln
|
WO2022067348A1
(en)
|
2020-09-28 |
2022-03-31 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
MX2023003877A
(es)
|
2020-10-01 |
2023-04-18 |
Abionyx Pharma Sa |
Composiciones que comprenden complejos basados en proteina de union a lipidos para usarse en el tratamiento de enfermedades oculares.
|
US20230390406A1
(en)
|
2020-10-19 |
2023-12-07 |
Vaccitech North America, Inc. |
Star Polymer Drug Conjugates
|
EP4232453A1
(de)
|
2020-10-20 |
2023-08-30 |
Institut Curie |
Metallische trans-(n-heterocyclische carben)-amin-platin-komplexe und verwendungen davon zur behandlung von krebs
|
EP4240397A1
(de)
|
2020-11-05 |
2023-09-13 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd19/cd22-immuntherapie
|
WO2022154127A1
(ja)
|
2021-01-18 |
2022-07-21 |
味の素株式会社 |
化合物またはその塩、およびそれらにより得られる抗体
|
EP4279500A1
(de)
|
2021-01-18 |
2023-11-22 |
Ajinomoto Co., Inc. |
Verbindung oder salz davon und damit hergestellter antikörper
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Cd3及びcldn6に結合するヘテロ二量体抗体
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
WO2022191283A1
(ja)
|
2021-03-11 |
2022-09-15 |
味の素株式会社 |
化合物またはその塩、およびそれらにより得られる抗体
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
JPWO2022196675A1
(de)
|
2021-03-16 |
2022-09-22 |
|
|
BR112023018189A2
(pt)
|
2021-03-19 |
2023-10-24 |
Heidelberg Pharma Res Gmbh |
Conjugados de anticorpos de amatoxina específicos de linfócitos b, composição famacêutica e uso relacionados
|
WO2022211508A1
(ko)
|
2021-03-30 |
2022-10-06 |
주식회사 레고켐바이오사이언스 |
인간 cldn18.2에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
AU2022253902A1
(en)
|
2021-04-10 |
2023-11-02 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
AU2022258815A1
(en)
|
2021-04-15 |
2023-10-19 |
Abionyx Pharma Sa |
Use of lipid binding protein-based complexes in organ preservation solutions
|
AU2022262644A1
(en)
|
2021-04-23 |
2023-11-09 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
WO2023288236A1
(en)
|
2021-07-14 |
2023-01-19 |
Seagen Inc. |
Antibody masking domains
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
WO2023054706A1
(ja)
|
2021-09-30 |
2023-04-06 |
味の素株式会社 |
抗体および機能性物質のコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
US20230355792A1
(en)
|
2022-04-07 |
2023-11-09 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|